These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8329500)

  • 1. Lack of effect of inositol treatment in chronic schizophrenia.
    Levine J; Umansky R; Ezrielev G; Belmaker RH
    Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):673-5. PubMed ID: 8329500
    [No Abstract]   [Full Text] [Related]  

  • 2. CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia.
    Levine J; Goldberger I; Rapaport A; Schwartz M; Schield C; Elizur A; Belmaker RH; Shapiro J; Agam G
    Eur Neuropsychopharmacol; 1994 Dec; 4(4):487-90. PubMed ID: 7894259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study.
    Silver H; Nassar A
    Biol Psychiatry; 1992 Apr; 31(7):698-704. PubMed ID: 1599987
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1991 Sep; 30(5):523-5. PubMed ID: 1932400
    [No Abstract]   [Full Text] [Related]  

  • 5. A double blind controlled study of ECT vs chlorpromazine in schizophrenia.
    Bagadia VN; Abhyankar RR; Doshi J; Pradhan PV; Shah LP
    J Assoc Physicians India; 1983 Oct; 31(10):637-40. PubMed ID: 6671932
    [No Abstract]   [Full Text] [Related]  

  • 6. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
    Grebb JA; Shelton RC; Taylor EH; Bigelow LB
    Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
    [No Abstract]   [Full Text] [Related]  

  • 7. Naltrexone in chronic negative schizophrenia.
    Marchesi GF; Santone G; Cotani P; Giordano A; Chelli F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():56A-57A. PubMed ID: 1498948
    [No Abstract]   [Full Text] [Related]  

  • 8. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.
    Glovinsky D; Kirch DG; Wyatt RJ
    Biol Psychiatry; 1992 May; 31(9):968-70. PubMed ID: 1637936
    [No Abstract]   [Full Text] [Related]  

  • 9. Clozapine decreases smoking in patients with chronic schizophrenia.
    McEvoy J; Freudenreich O; McGee M; VanderZwaag C; Levin E; Rose J
    Biol Psychiatry; 1995 Apr; 37(8):550-2. PubMed ID: 7619979
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute tryptophan depletion in schizophrenic patients treated with clozapine.
    George TP; Potenza MN; Degen K; Sernyak MJ; Woods S; McDougle CJ
    Arch Gen Psychiatry; 2002 Mar; 59(3):291-2. PubMed ID: 11879174
    [No Abstract]   [Full Text] [Related]  

  • 11. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.
    Lotstra F; Verbanck P; Mendlewicz J; Vanderhaeghen JJ
    Biol Psychiatry; 1984 Jun; 19(6):877-82. PubMed ID: 6378259
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia.
    Simhandl C; Meszaros K; Denk E; Thau K; Topitz A
    Can J Psychiatry; 1996 Jun; 41(5):317. PubMed ID: 8793154
    [No Abstract]   [Full Text] [Related]  

  • 13. Clozapine action on auditory P3 response in schizophrenia.
    Niznikiewicz MA; Patel JK; McCarley R; Sutton J; Chau DT; Wojcik J; Green AI
    Schizophr Res; 2005 Jul; 76(1):119-21. PubMed ID: 15927806
    [No Abstract]   [Full Text] [Related]  

  • 14. Naloxone-induced reduction of schizophrenic symptoms.
    Jørgensen HA; Cappelen C
    Acta Psychiatr Scand; 1982 May; 65(5):370-4. PubMed ID: 6126068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose naloxone administration in chronic schizophrenia.
    Cohen MR; Pickar D; Cohen RM
    Biol Psychiatry; 1985 May; 20(5):573-5. PubMed ID: 3886025
    [No Abstract]   [Full Text] [Related]  

  • 16. Fenfluramine and chronic schizophrenia.
    Shore D; Korpi ER; Bigelow LB; Zec RF; Wyatt RJ
    Biol Psychiatry; 1985 Mar; 20(3):349-52. PubMed ID: 3884057
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
    Feifel D; Macdonald K; Nguyen A; Cobb P; Warlan H; Galangue B; Minassian A; Becker O; Cooper J; Perry W; Lefebvre M; Gonzales J; Hadley A
    Biol Psychiatry; 2010 Oct; 68(7):678-80. PubMed ID: 20615494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-dose, double-blind study of ceruletide in the treatment of schizophrenia.
    Mattes JA; Hom W; Rochford JM
    Am J Psychiatry; 1985 Dec; 142(12):1482-4. PubMed ID: 3907376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial.
    Jungkunz G; Nedopil N; Rüther E
    Pharmacopsychiatry; 1984 May; 17(3):76-8. PubMed ID: 6739537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.